$-4.15
(Market cap
$18,824 Mln
Revenue (TTM)
$2,225 Mln
P/E Ratio
--
P/B Ratio
2.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-25.4 %
-
Industry P/E
--
-
EV/EBITDA
4.6
-
Debt to Equity
0.1
-
Book Value
$--
-
EPS
$-8.1
-
Face value
--
-
Shares outstanding
396,786,259
10 Years Aggregate
CFO
$16,449.87 Mln
EBITDA
$17,992.53 Mln
Net Profit
$13,724.47 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Moderna (MRNA)
| 60.9 | 0.3 | -17.9 | 74.0 | -28.6 | -25.5 | -- |
|
BSE Sensex
| -12.3 | -3.9 | -6.2 | -8.3 | 5.9 | 7.3 | 10.7 |
|
S&P 100
| 5.5 | 2.6 | 8.6 | 24.9 | 22.1 | 13.7 | 14.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Moderna (MRNA)
| -29.1 | -57.9 | -44.6 | -29.3 | 143.1 | 434.1 | 28.1 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Moderna (MRNA)
|
47.4 | 18,823.5 | 2,225.0 | -3,194.0 | -143.4 | -38.2 | -- | 2.5 |
| 303.1 | 40,318.1 | 4,286.9 | 577.2 | 9.8 | 88.2 | 75.7 | 36.7 | |
| 94.2 | 20,422.4 | 819.6 | -1,183.8 | -141.4 | -143.4 | -- | 29.0 | |
| 74.5 | 12,308.8 | 1,057.9 | -326.6 | -16.4 | -58.9 | -- | 25.0 | |
| 183.5 | 30,617.8 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 22.8 | 5.0 | |
| 163.9 | 16,478.1 | 3,102.4 | 668.6 | 27.4 | 20.9 | 25.2 | 4.8 | |
| 635.5 | 66,620.0 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 15.5 | 2.1 | |
| 14.8 | 13,613.9 | 0.0 | -872.2 | -- | -287.7 | -- | 24.7 | |
| 549.9 | 23,635.2 | 3,169.8 | 1,287.4 | 51.4 | 20.6 | 20.6 | 4.0 | |
| 446.8 | 113,588.1 | 12,255.1 | 4,338.3 | 31.7 | 23.7 | 26.5 | 5.9 |
Shareholding Pattern
View DetailsAbout Moderna (MRNA)
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and... pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Read more
-
CEO & Director
Mr. Stephane Bancel
-
CEO & Director
Mr. Stephane Bancel
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Moderna (MRNA)
What is the current share price of Moderna Inc (MRNA) Today?
The share price of Moderna Inc (MRNA) is $47.44 (NASDAQ) as of 05-Jun-2026 16:28 EDT. Moderna Inc (MRNA) has given a return of -28.63% in the last 3 years.
What is the current PB & PE ratio of Moderna Inc (MRNA)?
Since, TTM earnings of Moderna Inc (MRNA) is negative, P/E ratio is not available.
The P/B ratio of Moderna Inc (MRNA) is 2.54 times as on 05-Jun-2026, a 43 discount to its peers’ median range of 4.45 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-4.10
|
1.34
|
|
2024
|
-4.50
|
1.47
|
|
2023
|
-8.33
|
2.84
|
|
2022
|
8.70
|
3.80
|
|
2021
|
8.97
|
7.74
|
What is the 52 Week High and Low of Moderna Inc (MRNA)?
The 52-week high and low of Moderna Inc (MRNA) are Rs 59.55 and Rs 22.28 as of 07-Jun-2026.
What is the market cap of Moderna Inc (MRNA)?
Moderna Inc (MRNA) has a market capitalisation of $ 18,824 Mln as on 05-Jun-2026. As per SEBI classification, it is a Large Cap company.
Should I invest in Moderna Inc (MRNA)?
Before investing in Moderna Inc (MRNA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.